This Little Diagnostic Went To Market...

Written By Kenny Kane

[audio mp3="https://pdcn.co/e/rss.art19.com/episodes/f136acd4-f0a5-4f8d-abef-b6303d314eff.mp3?rss_browser=BAhJIgljdXJsBjoGRVQ%3D--435795d5c850773aaa4739d968bd77a1dfd6f301"][/audio] This Little Diagnostic Went To Market...

On the show today, I'm thrilled to welcome – LIVE IN STUDIO — Liz Cormier-May, CEO of Mammogen, and Marty Keiser, CEO at IV Bioholdings. It's hard to blend funny, entertaining wit with healthcare jargon like diagnostics, market access, go-to-market strategy, etc. And yet, somehow, we did it. The process is gnarly and ridiculous but, now more than ever, it's actually possible to NOT GET CANCER because of much more accessible and affordable diagnostics. Some of them are free; some are even over the counter. But getting into the hands of doctors or retail consumers is a whole other story, let alone issues with the FDA and safety. Well, we cut through all that crap and get to the brass taxes of how the only real thing moving the needle are consumers who vote with their wallets.

For more information, visit https://OffScripMedia.com and follow @MZOutofPatients, @MatthewZachary, @VaxOnPod, and @OffScripMedia on Twitter.


See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kenny Kane

Kenny Kane is an entrepreneur, writer, and nonprofit innovator with 15+ years of experience leading organizations at the intersection of business, technology, and social impact. He is the CEO of Firmspace, CEO of the Testicular Cancer Foundation, and CTO/co-founder of Gryt Health.

A co-founder of Stupid Cancer, Kenny has built national awareness campaigns and scaled teams across nonprofits, health tech, and real estate. As an author, he writes about leadership, resilience, and building mission-driven organizations.

Previous

Stupid Cancer: You Know What It Is
Next

VAX ON: The Epsilon Variant Is But One Douchebag Away